Their study disclosed that the loss of heterozygosity at the BRCA1 locus “...occurs in pancreatic cancers of germline BRCA1 mutation carriers, acting as a ‘second-hit’ event contributing to pancreatic tumorigenesis.” They concluded that BRCA1 germline mutations may be considered for PC screening. This evidence concerns the gene BRCA1 and pancreatic neoplasm.